Testing a new combination treatment for advanced lung cancer with specific genetic markers

Plain-English translation of NCT06962865 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether , a new medication, works better when combined with furmonertinib (an existing lung cancer drug) compared to furmonertinib alone. You would be eligible if you have advanced non-small cell lung cancer with two specific genetic markers: an EGFR mutation and MET positivity. The trial will compare how well the two-drug combination controls your cancer and how safe it is.

Some patients with advanced lung cancer have cancers that are positive for both EGFR and MET genetic markers, and these tumors can become resistant to single-drug treatments. This trial is exploring whether adding this new medication to an existing treatment might help people with this specific type of cancer live longer and control their disease better.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced lung cancer (stage IIIB, IIIC, or IV) that cannot be treated with surgery or radiation
your cancer has not been treated with chemotherapy or other systemic cancer drugs before
your cancer has specific genetic markers: an EGFR mutation (exon 19 deletion or L858R) and MET positivity
you are between 18 and 75 years old and in good enough health to tolerate treatment (ECOG performance status 0 or 1)
you are able to provide tumor tissue samples for testing
you have a life expectancy of at least 12 weeks

You likely don't qualify if…

you have cancer that has spread to your brain, spinal cord, or protective membranes around the brain
you have previously taken MET inhibitors or antibody-drug conjugates
you have serious heart disease, active tuberculosis, or untreated interstitial lung disease
you have HIV, AIDS, or active hepatitis B or C
you are unable to swallow pills or have severe digestive problems that would prevent you from absorbing oral medications

What participation looks like

You would be randomly assigned to receive either the new medication combined with furmonertinib, or furmonertinib alone. You would take these medications by mouth as directed and attend regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and any side effects you might experience. The study involves about 80 participants total and will assess both how effective the treatment is and how safe it is for you.

AI-generated summary from trial data · Aug 1, 2026 · Not medical advice

Trial locations(34 sites)

China

Beijing Chest Hospital,Capital Medical Unniversity, Beijing

The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing

Binzhou Medical University Hospital, Binzhou

Jilin Cancer Hospital, Changchun

The Second Xiangya Hospital Of Central South University, Changsha